


Performance for the month

HIGHLIGHTS

2,906.7p	NAV per share	£17.2m	Net portfolio cash flow ¹
+5.0%	NAV per share movement	3.6x	Financing cover ²
£1.6bn	Net asset value	+66%	Total shareholder return (5Y) ⁴

NAV PER SHARE



HIGHLIGHTS







PIP's portfolio generated £24.6m of distributions $^{\rm 1}$ during the month. This included:

- £10.0m from Ares Management, from the sale of National Veterinary Associates, the largest private owner of independent veterinary hospitals in the United States.
- £1.4m from EQT Greater China, from the sale of LBX Pharmacy, a China-based pharmacy chain.
- £1.4m from Clessidra Capital Partners, from the sale of Fides Spa, an Italy-based business which offers credit management and legal collection services.

NEW COMMITMENTS



PIP made two new commitments during the month amounting to $\pm 5.4 m$. This included:

 A £2.7m co-investment, alongside Insight Venture Partners, in Armis, a cloud-based Internet-of-Things cyber security provider.

KEY FIGURES

	29 Feb 2020	31 Jan 2020
Portfolio value	£1,490m	£1,428m
Net available cash ⁵	£148m	£135m
ALN ⁶ share of portfolio	(£66m)	(£65m)
Net asset value	£1,572m	£1,498m
NAV per share	2,906.7p	2,768.7p

	29 Feb 2020	31 Jan 2020
Ordinary share price	2,160.0p	2,435.0p
Ordinary share price discount	(26%)	(12%)
Undrawn loan facility ⁷	£179m	£174m
Available finance ⁸	£327m	£309m
Outstanding commitments	£506m	£490m

FUND REPORTING DATE ANALYSIS®

2

1. Dec-19: 45% 2. Sep-19: 50% 3. Jun-19: 3% 4. New investments held at cost: 2%

ABOUT PIE

PIP is a listed FTSE 250 private equity investment trust, overseen by an independent Board of Directors and managed by Pantheon, one of the leading investment managers globally. PIP offers a differentiated entry point to private equity through an investment company of scale with risk managed through selection and diversification, providing exposure to the excellent growth potential generated by some of the best private equity managers in the world.

ABOUT PANTHEON

Pantheon is a leading global private equity, infrastructure, real assets and debt fund investor that invests on behalf of over 550 investors. Founded in 1982, Pantheon has developed an established reputation in primary, co-investment and secondary private asset solutions across all stages and geographies. Pantheon has \$47.1 billion in AUM ¹⁰ (as at 30 September 2019) and 315 employees (as at 1 January 2020), including 96 investment professionals, located across offices in London, San Francisco, New York, Hong Kong, Seoul, Bogotá, Tokyo and Dublin.



Performance for nine months





NET CASHFLOW

PIP's portfolio generated net cash¹ of £108.6m during the nine months to 29 February 2020, with distributions of £191.5m relative to £82.9m of calls from existing commitments to private equity funds.

NEW COMMITMENTS

- PIP made 34 new investments in the nine-month period to 29 February 2020, amounting to £157.3m in commitments.
- PIP committed to 14 secondaries (£41.7m), six primaries (£51.3m) and 14 co-investments (£64.3m).

KEY FIGURES

	29 Feb 2020	31 May 2019
Portfolio value	£1,490m	£1,450m
Net available cash ⁵	£148m	£141m
ALN ⁶ share of portfolio	(£66m)	(£92m)
Net asset value	£1,572m	£1,499m
NAV per share	2,906.7p	2,770.6p

	29 Feb 2020	31 May 2019
Ordinary share price	2,160.0p	2,225.0p
Ordinary share price discount	(26%)	(20%)
Undrawn loan facility ⁷	£179m	£182m
Available finance ⁸	£327m	£323m
Outstanding commitments	£506m	£521m


CURRENCY EXPOSURE OF PORTFOLIO9

	0	0.4	4 1100 740	0.5115.400	0.000.00	4.04
1	2	34	1. USD: 76%	2. EUR: 19%	3. GBP: 3%	4. Other: 2%



Maximising long-term capital growth

PIP'S LONG-TERM PERFORMANCE



^{*} Includes the effects of dividends, capital repayments and warrants. NAV figure based upon adjusted NAV per share where applicable

ANNUALISED PERFORMANCE AS AT 29 FEBUARY 2020

					Since
	1yr	3yrs	5yrs	10yrs	inception
NAV per share	14.6%	11.6%	13.9%	13.2%	11.7%
Ordinary share price	3.3%	8.2%	10.6%	16.4%	11.2%
FTSE All-Share, Total Return	(1.4%)	1.5%	3.6%	6.8%	7.4%
MSCI World, Total Return (Sterling)	5.9%	6.3%	10.2%	11.1%	7.8%

LARGEST HOLDINGS

Largest managers by value ¹¹	Region	% of portfolio
1 Providence Equity Partners	USA	5.6%
2 Venture Fund ¹⁵	USA	4.6%
3 Essex Woodlands	USA	3.7%
4 Apax Partners SA	Europe	2.9%
5 Baring Private Equity Asia Ltd	Asia and EM	2.7%

Largest companies by value ¹²	Country	Sector	portfolio
1 EUSA Pharma	UK	Healthcare	2.8%
2 Energy Company ¹⁵	USA	Energy	1.2%
3 Dermatology Company ¹⁵	USA	Healthcare	1.0%
4 Ophthalmology Company ¹⁵	USA	Healthcare	1.0%
5 Abacus Data Systems	USA	IT	1.0%



SHAREHOLDER INFORMATION

Trading symbol

GB0004148507

Admission to trading September 1987 **Shares in issue** 54,089,447

CONTACT

Vicki Bradley
vicki.bradley@pantheon.com
+44 20 3356 1800

www.piplc.com



Risk managed through diversification¹

As at 29 February 2020

INVESTMENT TYPE



1	Secondary	36%
2	Co-investments	34%
3	Primary	30%

REGION




1	USA	54%
2	Europe	29%
3	Asia and EM ¹⁴	10%
4	Global ¹⁴	7%




1	Small/Mid Buyout	39%
2	Large/Mega Buyout	26%
3	Growth	20%
4	Special Situations	10%
5	Venture	5%

FUND VINTAGE



1	2019 and later	89
2	2018	149
3	2017	149
4	2016	16%
5	2015	169
6	2014	5%
7	2013	39
8	2012	3%
9	2011	49
10	2010	19
11	2009	29
12	2008	69
13	2007 and earlier	89

SECTOR12



Information Technology	24%
Healthcare	19%
Consumer	15%
Financials	12%
Industrials	10%
Energy	8%
Communication Services	7%
Others	5%
	Healthcare Consumer Financials Industrials Energy Communication Services

NOTES

- ¹ Figures are stated net of movements associated with the ALN share of the
- Ratio of net available cash, portfolio value and undrawn loan facility to outstanding
- Taxes relate to withholding taxes on investment distributions.
- ⁴ Based on the change in ordinary share price over the period.
- Net available cash calculated as cash and net current assets/(liabilities) less undistributed net cashflows associated with the ALN.
- The Asset Linked Note ("ALN") refers to the unlisted 10-year note issued on 31 October 2017 whose cost and repayments are linked to a reference portfolio consisting of the Company's older vintage funds.
- PIP maintains a £179m multi-currency credit facility. The sterling-equivalent value at 29 February 2020 reflects movements in exchange rates as it comprises facilities denominated in Euros and US dollars. The loan facility remains fully
- Available finance calculated as net available cash and undrawn loan facility.
- PIP's valuation policy for private equity funds is based on the latest valuations reported by the managers of the funds in which PIP has holdings. In the case of

DISCLOSURES

This document and the information contained herein is the proprietary information of PIP; it may not be reproduced, amended, or used for any other purpose, without the prior written permission of PIP. This document is distributed by Pantheon, a firm that is authorised and regulated by the Financial Conduct Authority ("FCA") in the United Kingdom. The information and any views contained in this document are provided for general information only. Nothing in this document constitutes an offer, recommendation, invitation, inducement or solicitation to invest in PIP. Nothing contained in this document is intended to constitute legal, tax, securities or investment advice. The general opinions and information contained in this publication should not be acted or relied upon by any person without obtaining specific and relevant legal, tax, securities or investment advice. You should remember that the value of an investment in PIP, and any income from it, may go down as well as up, and is not guaranteed, and investors may not get back the amount of money invested. In addition, past performance is not necessarily indicative of future results. You should note that investments in private equity may be illiquid and may involve a high degree of risk, including potential loss of principal invested.

PIP's valuation as at 29 February 2020, 47% of reported valuations are dated 31 December 2019 or later. The Fund Reporting Date Analysis at 29 February 2020 shows the respective reporting dates on which the valuation was based. Where receipt of post completion valuation reports is pending, any new secondaries or coinvestments are held at cost. Pantheon is closely monitoring the market developments relating to COVID-19 in order to measure the potential impact on the valuation of PIP's underlying investment portfolio, which will be reflected in the future announcements of monthly NAVs. A full version of PIP's valuation policy can be found in the Notes to the Financial Statements section of PIP's 2019 Annual Report and Accounts.

- ¹⁰ The figure includes assets subject to discretionary or non-discretionary management, advice or those limited to a reporting function.
- ¹¹ As at 29 February 2020.
- $^{\rm 12}\,\rm Based$ on valuations as at 30 September 2019 adjusted for known calls and distributions to 30 November 2019. The chart on page 4 accounts for 94% of PIP's
- ¹³ Excludes cash flows attributable to the ALN.
- $^{\rm 14}{\rm EM}$ is Emerging Markets. The Global category contains funds with no target allocation equal to or exceeding 60% of any particular region.

In addition, most of PIP's investments are in funds whose principal investment focus is outside the UK. Movements in exchange rates between sterling and other currencies therefore affects the value of PIP's investments. Further, the market price of PIP's shares may reflect a discount in the net asset value of PIP's shares, and this discount may increase or reduce due to market factors which are unrelated to PIP's NAV or performance. Loss may be multiplied since PIP invests in a range of private equity strategies including buyouts that commonly use gearing. PIP's investment valuation method is reliant on financial information provided by underlying funds and companies into which it invests. Valuation methods used by those funds and companies may be inconsistent. Pantheon has taken reasonable care to ensure that the information contained in this document is accurate at the date of publication. However, no warranty or guarantee (express or implied) is given by Pantheon as to the accuracy of the information in this document, and to the extent permitted by applicable law, Pantheon specifically disclaims any liability for errors inaccuracies or omissions in this document and for any loss or damage resulting from its use. Copyright @ Pantheon 2020. All rights reserved.